Investors Concentrate Bets on U.S. Healthcare as M&A, Spending Rise

Merger-and-acquisition activity in the U.S. healthcare sector accelerated toward the end of 2025, with the biotechnology segment accounting for the largest share of deals by volume as of Oct. 27, 2025, according to a J.P. Morgan report. Health care equipment and pharmaceuticals also registered strong transaction volumes.

The J.P. Morgan report pointed to strategic consolidation and portfolio reshaping among companies and investors as drivers of the uptick in dealmaking.

Federal and private spending projections align with the increase in market activity. The Peterson Center on Healthcare projected U.S. health spending would reach $5.9 trillion in 2026 and estimated that health spending will represent more than one-fifth of the U.S. economy by 2033. The center highlighted rising demand for medical services, an aging population, and continued investment in drug development and medical technologies as factors behind the growth.

Some investors seeking focused exposure have shifted capital into sector-specific exchange-traded funds. The State Street Health Care Select Sector SPDR ETF (XLV), which tracks healthcare companies in the S&P 500, recorded about $911 million in net inflows through April 17, 2026, based on ETF flow data. XLV holds large-cap biotechnology, pharmaceutical and medical equipment companies.

Market participants cited broader adoption of artificial intelligence in drug discovery, diagnostics and operations as a development that may affect cost structures and product development timelines across biotechnology and device makers.

Analysts and reports identified demographic shifts, patent-driven drug pipelines and higher spending on medical services and technology as background trends. The rise in deal activity in late 2025, combined with near-term and long-term spending forecasts, coincided with inflows into healthcare-focused funds.